Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis B surface antigen
- Development stage
- Unknown
- Lead developer
- Helmholtz Zentrum München
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant hepatitis B surface antigen (HBsAg) is a protein biologic that serves as a key component of the TherVacB therapeutic vaccine regimen. Developed by Helmholtz Munich and the Technical University of Munich, it is produced as virus-like particles (VLPs) using recombinant DNA technology. In the TherVacB protocol, it is formulated with Th1-inducing adjuvants, such as saponin QS21 and monophosphoryl lipid A, and administered as a 'prime' to stimulate the immune system against the hepatitis B virus. This priming is followed by a 'boost' with a viral vector (MVA-HBVAC). The drug is currently being evaluated in Phase 1b/2a clinical trials for the treatment of chronic hepatitis B, aiming to induce a functional cure by restoring effective B-cell and T-cell responses.
- Other names
- HBsAg
02
Targets
Hepatitis B surface antigen-derived peptide–Major Histocompatibility Complex class I complex (HBsAg-pMHC I)Hepatitis B surface antigen-derived peptide–Major Histocompatibility Complex class II complexSBP (Hepatitis B surface antigen-binding protein)HBsAg-specific BCR (HBsAg-specific B-cell receptor)B2GP1 (Beta-2-glycoprotein I)
Beyond the preview
Go deeper on recombinant hepatitis B surface antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis B surface antigen.